Challenges in Prescribing Clozapine in the Era of COVID-19: A Review Focused on Immunological Implications

키워드

참고문헌 (101)

1. Siskind D, "Consensus statement on the use of clozapine during the COVID-19 pandemic", J Psychiatry Neurosci, 45, pp.222~223 (2020)
2. Tsamakis K, "Oncology during the COVID-19 pandemic : challenges, dilemmas and the psychosocial impact on cancer patients", Oncol Lett, 20, pp.441~447 (2020)
3. Kreuzer PM, "SARS-CoV-2 risk management in clinical psychiatry : a few considerations on how to deal with an unrivaled threat", Front Psychiatry, 11, pp.550~ (2020)
4. Dickerson F, "Schizophrenia is associated with an aberrant immune response to Epstein-Barr virus", Schizophr Bull, 45, pp.1112~1119 (2019)
5. Burgdorf KS, "Large-scale study of Toxoplasma and cytomegalovirus shows an association between infection and serious psychiatric disorders", Brain Behav Immun, 79, pp.152~158 (2019)
6. Nudel R, "Immunity and mental illness : findings from a Danish population-based immunogenetic study of seven psychiatric and neurodevelopmental disorders", Eur J Hum Genet, 27, pp.1445~1455 (2019)
7. Røge R, "Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far?", Schizophr Res, 140, pp.204~213 (2012)
8. Walls AC, "Structure, function, and antigenicity of the SARSCoV-2 spike glycoprotein", Cell, 181, pp.281~292 (2020)
9. Zhang JJ, "Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China", Allergy, 75, pp.1730~1741 (2020)
10. Kim DH, "Understanding and interpretation of case fatality rate of coronavirus disease 2019", J Korean Med Sci, 35, pp.e137~ (2020)
11. Shi Y, "COVID-19 infection : the perspectives on immune responses", Cell Death Differ, 27, pp.1451~1454 (2020)
12. Prieto-Pérez L, "Histiocytic hyperplasia with hemophagocytosis and acute alveolar damage in COVID-19infection", Mod Pathol, 33, pp.2139~2146 (2020)
13. Fathi N, "Lymphopenia in COVID-19 : therapeutic opportunities", Cell Biol Int, 44, pp.1792~1797 (2020)
14. Ragab D, "The COVID-19 cytokine storm; what we know so far", Front Immunol, 11, pp.1446~ (2020)
15. Ruan Q, "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China", Intensive Care Med, 46, pp.846~848 (2020)
16. Picchianti Diamanti A, "Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern : the fragile balance between infections and autoimmunity", Int J Mol Sci, 21, pp.3330~ (2020)
17. Kahan SM, "T cell exhaustion during persistent viral infections", Virology, 479-480, pp.180~193 (2015)
18. Diao B, "Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019(COVID-19)", Front Immunol, 11, pp.827~ (2020)
19. Berger A, "Th1 and Th2 responses: what are they?", BMJ, 321, pp.424~ (2000)
20. Kidd P, "Th1", Th2 balance : the hypothesis, its limitations, and implications for health and disease, 2003, pp.8, 223~246
21. Müller N, "Inflammation in schizophrenia : pathogenetic aspects and therapeutic considerations", Schizophr Bull, 44, pp.973~982 (2018)
22. Mokhtari R, "The major histocompatibility complex(MHC)in schizophrenia : a review", J Clin Cell Immunol, 7, pp.479~ (2016)
23. Steiner J, "Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity", Eur Arch Psychiatry Clin Neurosci, 260, pp.509~518 (2010)
24. Schwarz MJ, "The Th2-hypothesis of schizophrenia : a strategy to identify a subgroup of schizophrenia caused by immune mechanisms", Med Hypotheses, 56, pp.483~486 (2001)
25. Pollak TA, "Autoimmune psychosis : an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin", Lancet Psychiatry, 7, pp.93~108 (2020)
26. Chiang SS, "Is T-helper type 2 shift schizophrenia-specific? Primary results from a com-parison of related psychiatric disorders and healthy controls", Psychiatry Clin Neurosci, 67, pp.228~236 (2013)
27. Miller BJ, "Meta-analysis of lymphocytes in schizophrenia : clinical status and antipsychotic effects", Biol Psychiatry, 73, pp.993~999 (2013)
28. Ezeoke A, "A systematic, quantitative review of blood autoantibodies in schizophrenia", Schizophr Res, 150, pp.245~251 (2013)
29. Mohagheghi M, "Determining the IgM and IgG antibodies titer against HSV1, HSV2 and CMV in the serum of schizophrenia patients", Hum Antibodies, 26, pp.87~93 (2018)
30. Md. Mamun Al-Amin, "Effects of Antipsychotics on the Inflammatory Response System of Patients with Schizophrenia in Peripheral Blood Mononuclear Cell Cultures", Clinical Psychopharmacology and Neuroscience, 11(3), pp.144~151 (2013), 대한정신약물학회
31. Karageorgiou V, "Neutrophil-tolymphocyte ratio in schizophrenia : a systematic review and meta-analysis", Schizophr Res, 206, pp.4~12 (2019)
32. Kulaksizoglu B, "Relationship between neutrophil", lymphocyte ratio with oxidative stress and psychopathology in patients with schizophrenia, 2016, pp.12, 1999~2005
33. Müller N, "The role of inflammation in schizophrenia", Front Neurosci, 9, pp.372~ (2015)
34. Momtazmanesh S, "Cytokine alterations in schizophrenia : an updated review", Front Psychiatry, 10, pp.892~ (2019)
35. West PK, "Microglia responses to interleukin-6 and type I interferons in neuroinflammatory disease", Glia, 67, pp.1821~1841 (2019)
36. Al-Hakeim HK, "IL-6, IL-18, sIL-2R, and TNF proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation", J Affect Disord, 182, pp.106~114 (2015)
37. Goldsmith DR, "A meta-analysis of blood cytokine network alterations in psychiatric patients : comparisons between schizophrenia, bipolar disorder and depression", Mol Psychiatry, 21, pp.1696~1709 (2016)
38. Sperner-Unterweger B, "Effects of clozapine on hematopoiesis and the cytokine system", Biol Psychiatry, 34, pp.536~543 (1993)
39. Maes M, "Immune-inflammatory markers in schizophrenia : comparison to normal controls and effects of clozapine", Acta Psychiatr Scand, 89, pp.346~351 (1994)
40. Merrill DB, "Adverse cardiac effects associated with clozapine", J Clin Psychopharmacol, 25, pp.32~41 (2005)
41. Mouaffak F, "Clozapine-induced serositis : review of its clinical features, pathophysiology and management strategies", Clin Neuropharmacol, 32, pp.219~223 (2009)
42. Lowe CM, "Characterization and clinical management of clozapine-induced fever", Ann Pharmacother, 41, pp.1700~1704 (2007)
43. Löffler S, "Clozapine mobilizes CD34＋ hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia", J Clin Psychopharmacol, 30, pp.591~595 (2010)
44. Maes M, "In vivo immunomodulatory effects of clozapine in schizophrenia", Schizophr Res, 26, pp.221~225 (1997)
45. Schmitt A, "Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication", Neuropsychiatr Dis Treat, 1, pp.171~177 (2005)
46. Song C, "Immunosuppressive effects of clozapine and haloperidol : enhanced production of the interleukin-1 receptor antagonist", Schizophr Res, 42, pp.157~164 (2000)
47. Chen ML, "Clozapine inhibits Th1 cell differentiation and causes the suppression of IFN- production in peripheral blood mononuclear cells", Immunopharmacol Immunotoxicol, 34, pp.686~694 (2012)
48. Giridharan VV, "Clozapine prevents poly(I : C)induced inflammation by modulating NLRP3 pathway in microglial cells", Cells, 9, pp.577~ (2020)
49. Gooding R, "Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2", Br J Cancer, 72, pp.452~455 (1995)
50. "Severe Mental Illness and Risks from COVID-19" (2020)[URL]
51. Stoecker ZR, "Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population : a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months", Int Clin Psychopharmacol, 32, pp.155~160 (2017)
52. Abdelmawla N, "Clozapine and risk of pneumonia", Br J Psychiatry, 194, pp.468~469 (2009)
53. Risha Govind, "Clozapine treatment and risk of COVID-19 infection: retrospective cohort study", The British Journal of Psychiatry, 219(1), pp.368~374 (2021), Royal College of Psychiatrists[DOI]
54. de Leon J, "A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology", Psychother Psychosom, 89, pp.200~214 (2020)
55. de Leon J, "Clozapine is strongly associated with the risk of pneumonia and inflammation", Gen Psychiatr, 33, pp.e100183~ (2020)
56. Monica Fung, "COVID-19 in Immunocompromised Hosts: What We Know So Far", Clinical Infectious Diseases, 72(2), pp.340~350 (2021), Oxford University Press (OUP)[DOI]
57. Amaral L, "Antimicrobial activity of phenothiazines", In Vivo, 18, pp.725~731 (2004)
58. Anderson AG, "Inhibition of Epstein-Barr virus lytic reactivation by the atypical antipsychotic drug clozapine", Viruses, 11, pp.450~ (2019)
59. Yang N, "Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19", Int J Biol Sci, 16, pp.1724~1731 (2020)
60. Cavignac Y, "Herpesviruses and autophagy:catch me if you can!", Viruses, 2, pp.314~333 (2010)
61. Mancinelli R, "Multifaceted roles of GSK-3 in cancer and autophagy-related diseases", Oxid Med Cell Longev, 2017, pp.4629495~ (2017)
62. Kang UG, "The effects of clozapine on the GSK-3-mediated signaling pathway", FEBS Lett, 560, pp.115~119 (2004)
63. Azoulay-Alfaguter I, "Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth", Oncogene, 34, pp.4613~4623 (2015)
64. Avrahami L, "GSK-3-TSC axis governs lysosomal acidification through autophagy and endocytic pathways", Cell Signal, 71, pp.109597~ (2020)
65. Kim SH, "The antipsychotic agent clozapine induces autophagy via the AMPK-ULK1-Beclin1 signaling pathway in the rat frontal cortex", Prog Neuropsychopharmacol Biol Psychiatry, 81, pp.96~104 (2018)
66. Mijaljica D, "Autophagy", virophagy : a"disposal strategy"to combat COVID-19, 2020, pp.16, 2271~2272
67. (2020)[URL]
68. Kim SH, "Electroconvulsive seizures induce autophagy by activating the AMPK signaling pathway in the rat frontal cortex", Int J Neuropsychopharmacol, 23, pp.42~52 (2020)
69. Villoutreix BO, "Prevention of COVID-19 by drug repurposing : rationale from drugs prescribed for mental disorders", Drug Discov Today, 25, pp.1287~1290 (2020)
70. "Encephale", 2020, S35~S39
71. Pirofski LA, "Pathogenesis of COVID-19 from the perspective of the damage-response framework", mBio, 11, pp.e01175~20 (2020)
72. Štuhec M, "Clozapine-induced elevated C-reactive protein and fever mimic infection", Gen Hosp Psychiatry, 35, pp.680~ (2013)
73. Kadiyala PK, "Clozapine induced eosinophilia : an often neglected important adverse effect", Indian J Psychiatry, 57, pp.429~430 (2015)
74. Ponsford M, "Clozapine is associated with secondary antibody deficiency", Br J Psychiatry, 214, pp.1~7 (2018)
75. Fülöp T, "Human inflammaging", Gerontology, 65, pp.495~504 (2019)
76. Valiathan R, "Effects of ageing on the immune system : infants to elderly", Scand J Immunol, 83, pp.255~266 (2016)
77. Heather E. Soder, "Elevated Neutrophil to Lymphocyte Ratio in Older Adults with Cocaine Use Disorder as a Marker of Chronic Inflammation", Clinical Psychopharmacology and Neuroscience, 18(1), pp.32~40 (2020), 대한정신약물학회[DOI]
78. Franceschi C, "Inflamm-aging. An evolutionary perspective on immunosenescence", Ann N Y Acad Sci, 908, pp.244~254 (2000)
79. Shivakumar V, "Do schizophrenia patients age early?", Asian J Psychiatr, 10, pp.3~9 (2014)
80. Nguyen TT, "Systemic biomarkers of accelerated aging in schizophrenia : a critical review and future directions", Schizophr Bull, 44, pp.398~408 (2018)
81. Okazaki S, "Epigenetic clock analysis of blood samples from Japanese schizophrenia patients", NPJ Schizophr, 5, pp.4~ (2019)
82. Higgins-Chen AT, "Schizophrenia and epigenetic aging biomarkers : increased mortality, reduced cancer risk, and unique clozapine effects", Biol Psychiatry, 88, pp.224~235 (2020)
83. Gross A, "Decreased production of reactive oxygen species by blood monocytes caused by clozapine correlates with EEG slowing in schizophrenic patients", Neuropsychobiology, 47, pp.73~77 (2003)
84. Jiang L, "Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase", J Neuroinflammation, 13, pp.110~ (2016)
85. Couper KN, "IL-10 : the master regulator of immunity to infection", J Immunol, 180, pp.5771~5777 (2008)
86. Sandmand M, "Is ageing associated with a shift in the balance between Type 1 and Type 2 cytokines in humans?", Clin Exp Immunol, 127, pp.107~114 (2002)
87. Wherry EJ, "Molecular and cellular insights into T cell exhaustion", Nat Rev Immunol, 15, pp.486~499 (2015)
88. de Leon J, "Serious respiratory infections can increase clozapine levels and contribute to side effects : a case report", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.1059~1063 (2003)
89. Shah RR, "Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes : hypothesis with implications for personalized medicine", Drug Metab Dispos, 43, pp.400~410 (2015)
90. Clark SR, "Elevated clozapine levels associated with infection : a systematic review", Schizophr Res, 192, pp.50~56 (2018)
91. Wiciński M, "Clozapine-induced agranulocytosis", granulocytopenia : mechanisms and monitoring, 2018, pp.25, 22~28
92. Hampson ME, "Clozapine-induced thrombocytosis", Br J Psychiatry, 176, pp.400~ (2000)
93. Kate N, "Clozapine associated thrombocytopenia", J Pharmacol Pharmacother, 4, pp.149~151 (2013)
94. Wise J, "Covid-19 and thrombosis: what do we know about the risks and treatment?", BMJ, 369, pp.m2058~ (2020)
95. Levi M, "Coagulation abnormalities and thrombosis in patients with COVID-19", Lancet Haematol, 7, pp.e438~ (2020)
96. Leung JG, "Clozapine treated patients and COVID-19 : ensuring continued care through collaboration", Schizophr Res, 222, pp.507~508 (2020)
97. Xavier Boland, "Clozapine in the Time of COVID-19", Clinical Psychopharmacology and Neuroscience, 18(3), pp.450~453 (2020), 대한정신약물학회[DOI]
98. Cranshaw T, "COVID-19 infection may cause clozapine intoxication : case report and discussion", Schizophr Bull, 46, pp.751~ (2020)
99. Dotson S, "Clozapine toxicity in the setting of COVID-19", Psychosomatics, 61, pp.577~578 (2020)
100. Siobhan Gee, "Management of clozapine treatment during the COVID-19 pandemic", Therapeutic Advances in Psychopharmacology, 10, pp.204512532092816~ (2020), SAGE Publications[DOI]
101. Kozloff N, "The COVID-19 global pandemic : implications for people with schizophrenia and related disorders", Schizophr Bull, 46, pp.752~757 (2020)

관련 논문AI추천